On October 12, 2025, Bristol‑Myers Squibb announced a definitive agreement to acquire Orbital Therapeutics for $1.5 billion in cash. The deal adds Orbital’s in‑vivo CAR‑T platform, including the lead candidate OTX‑201, a circular RNA‑encoded CAR targeting CD19 for autoimmune disease.
The acquisition expands BMS’s cell‑therapy portfolio beyond its two FDA‑approved CAR‑T products, Breyanzi and Abecma, by adding a platform that can generate CAR‑T cells inside the patient’s body, potentially reducing manufacturing complexity and cost.
By integrating Orbital’s RNA platform and lipid‑nanoparticle delivery technology, BMS aims to accelerate development of next‑generation therapies for autoimmune disorders and broaden its reach into the rapidly growing in‑vivo cell‑therapy market, positioning the company for long‑term growth beyond its legacy oncology assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.